Understanding Checkpoint Inhibitors in Cancer Therapy, Mechanisms of Action, Resistance and Future Challenges

Understanding Checkpoint Inhibitors in Cancer Therapy, Mechanisms of Action, Resistance and Future Challenges

Review Data

Q: Is the topic relevant to the journal area of interest? Is it contemporary and interesting for

researchers?

A: Excellent

 

Abstract & Keywords

Q: Are all required components included in the abstract? Are the keywords appropriately chosen?

A: Very good; In the last sentence of the Abstract, “program death” must be replaced with “programmed death” both times.

 

Goal

Q: Is the goal explicitly stated in the Introduction? Is its formulation clear and unambiguous?

A: Very good

 

Structure

Q: Is the paper's structure coherent? Is it in coherence with the goal of the paper?

A: Very good

 

Tools and Methods

Q: Are methods the author uses adequate and well used?

A: Good

 

Discussion & Conclusion

Q: Is it related to the results presented before? Do you consider them as coherent?

A: Good

 

Comments:

The Conclusion provides an apt summary of the current status of the field of immune checkpoint inhibitors research and development and the future directions in the field.

 

Literature

Q: Does the author utilize relevant literature?

A: Good

 

Author's knowledge

Q: What is the level of the author’s knowledge? Does the author utilize all recent contributions relevant to the topic?

A: Good

 

Length

Q: Is the length of the paper adequate to the significance of the topic? Do you suggest shortening the paper without losing its value?

A: Good

 

Figures & Tables

Q: Does the author use them suitably? Are legend and notations clear?

A: Very good

 

Writing style

Q: Is it clear and understandable?

A: Good

 

Further comments on the paper

Comments: This article offers a detailed and insightful review of the pathways involved in anticancer immune response, evasion and suppression of the immune system by cancer, mechanisms of action and success of immune checkpoint inhibitors (ICI), particularly programmed death-1 and programmed death-ligand inhibitors as well as mechanisms that result in resistance of cancer cells to ICI and the future challenges in this field.

 

Q: Would you recommend this manuscript for further publication?

A: Yes - Suitable to be published

If you have any questions and clarifications you can write to the journal.

Thanks,
Science Repository Team 

 
 

Author Info

Corresponding Author
Harman Saman
Consultant in Respiratory and Internal Medicine and Cancer Researcher, Hamad Medical Corporation-Qatar, Doha, Qatar

Article Info

Article Type
Review Article
Publication history
Received: Mon 24, Aug 2020
Accepted: Fri 25, Sep 2020
Published: Wed 30, Sep 2020
Copyright
© 2023 Harman Saman. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Hosting by Science Repository.
DOI: 10.31487/j.COR.2020.09.08